


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in this Application:

**Listing of Claims:**

1. (Currently amended) A chemical compound having formula I:



wherein:

R is selected from the group comprising alkyl, aryl and alkylaryl;

R' and R" are independently selected from the group comprising H, alkyl and alkylaryl, or

R' and R" together form an alkylene chain so as to provide, together with the C atom to which they are attached, a cyclic system;

Q is selected from the group comprising -O- and -CH<sub>2</sub>-;

X and Y are independently selected from the group comprising H, halogen, OH and -CH<sub>3</sub>;

Ar is a monocyclic aromatic ring moiety or a fused bicyclic aromatic ring moiety, either of which said ring moieties is carbocyclic or heterocyclic and is optionally substituted, any such substituent being selected from the group comprising halogen, halomethyl, oxo, hydroxy, carboxy, carboxyC<sub>1-16</sub> alkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl, aryloyloxy, amino, C<sub>1-6</sub>alkylamino, diC<sub>1-6</sub>alkylamino, cyano, azide, nitro, thiol, C<sub>1-6</sub> alkylthiol, sulphonyl, sulphoxide, hetocyclic groups, alkyl groups and aryl groups;

Z is selected from the group comprising H, alkyl and halogen; and

n is 0 or 1,

~~wherein when n is 0, Z' is -NH<sub>2</sub> and a double bond exists between position 3 and position 4, and~~

~~when n is 1, Z' is -O-~~

or a pharmaceutically acceptable derivative of a compound of formula I the derivative which upon administration to a recipient is capable of providing directly or indirectly a compound of formula I[[;]]

~~with the proviso that a compound or compounds of Formula I when n is 1 and X and Y are both H and Ar is unsubstituted C<sub>6</sub>H<sub>5</sub> are excluded except where R is CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub> and one of R' and R" is H and one of R' and R" is CH<sub>3</sub>.~~

2. (Original) A compound according to claim 1 wherein R is selected from the group comprising a C<sub>1-16</sub> primary or secondary alkyl group, a C<sub>5-7</sub> carbocyclic aryl group or a C<sub>1-6</sub>alkylC<sub>5-11</sub> aryl group.

3. (Previously presented) compound according to claim 2 wherein R is selected from the group CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub> and -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>.

4. (Previously presented) A compound according to claim 3 wherein R is -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>.

5. (Previously presented) A compound according to claim 1 wherein Ar is an optionally substituted C<sub>6</sub> monocyclic aromatic ring moiety.

6. (Original) A compound according to claim 5 wherein Ar is selected from the group comprising -C<sub>6</sub>H<sub>5</sub>, pCF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>-, pFC<sub>6</sub>H<sub>4</sub>-, pNO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>-, pClC<sub>6</sub>H<sub>4</sub>- and oClC<sub>6</sub>H<sub>4</sub>-.

7. (Canceled).

8. (Previously presented) A compound according to claim 1 wherein R' and R" are, independently, selected from the group comprising H, C<sub>1-6</sub> primary, secondary and tertiary alkyl, C<sub>1-3</sub>alkylC<sub>5-7</sub> aryl, or, when together they form an alkylene chain, they provide, together with the C atom to which they are attached, a C<sub>3-8</sub> carbocyclic aliphatic ring.

9. (Previously presented) A compound according to claim 8 wherein R' and R" are, independently, selected from the group comprising H, methyl, benzyl and [[-]]CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, or, R' and R" together with the C atom to which they are attached, provide a C<sub>5-6</sub> ring.

10. (Original) A compound according to claim 9 wherein R' and R" are each methyl.

11. (Original) A compound according to claim 9 wherein one of R' and R" is H and one of R' and R" is methyl.

12. (Previously presented) A compound according to claim 9 wherein R' and R", together with the C atom to which they are attached, provide a pentyl ring.

13. (Previously presented) A compound according to claim 1 wherein R' and R" correspond to the side chains of a naturally occurring amino acid.

14. (Canceled).

15. (Previously presented) A compound according to claim 1 wherein Q is O.

16. (Canceled).

17. (Currently amended) A compound according to claim 1 wherein ~~when n is 0~~, each of X and Y is F.

18. (Currently amended) A compound according to claim 1 wherein ~~when n is 0~~, X is OH and Y is H.

19. (Currently amended) A compound according to claim 1 wherein ~~when n is 0~~, X is H and Y is OH.

20. (Currently amended) A compound selected from the group comprising:

~~(E) 5 (2-Bromovinyl) 2' deoxyuridine 5' [para-fluorophenyl (methoxy L-alaninyl)]-phosphate;~~

~~(E) 5 (2-Bromovinyl) 2' deoxyuridine 5' [para-fluorophenyl (ethoxy L-alaninyl)]-phosphate;~~

~~(E) 5 (2-Bromovinyl) 2' deoxyuridine 5' [para-fluorophenyl (benzoxo L-alaninyl)]-phosphate;~~

~~(E) 5 (2-Bromovinyl) 2' deoxyuridine 5' [para-nitrophenyl (methoxy L-alaninyl)]-phosphate;~~

~~(E) 5 (2-Bromovinyl) 2' deoxyuridine 5' [para-nitrophenyl (ethoxy L-alaninyl)]-phosphate;~~

~~(E) 5 (2-Bromovinyl) 2' deoxyuridine 5' [para-nitrophenyl (benzoxo L-alaninyl)]-phosphate;~~

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [para (trifluoromethyl) phenyl (methoxy L alaninyl)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [para (trifluoromethyl) phenyl (ethoxy L alaninyl)] phosphate;

(E) 5 (2 Bromovinyl) 2' deoxyuridine 5' [para trifluorophenyl (benzoxy L alaninyl)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 chlorophenyl (methoxy L alaninyl)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 chlorophenyl (ethoxy L alaninyl)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 nitrophenyl (methoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 nitrophenyl (ethoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 nitrophenyl (benzoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 chlorophenyl (methoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 chlorophenyl (ethoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [4 chlorophenyl (benzoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 bromovinyl) 2' deoxyuridine 5' [para (trifluoromethyl) phenyl (benzoxy  $\alpha,\alpha$  dimethylglyciny)] phosphate;

(E) 5 (2 Bromovinyl) 2' deoxyuridine 5' [para nitrophenyl (methoxy  $\alpha,\alpha$  cycloleuciny)] phosphate;

(E) 5 (2 Bromovinyl) 2' deoxyuridine 5' [para nitrophenyl (ethoxy  $\alpha,\alpha$  cycloleuciny)] phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-nitrophenyl-(benzoxo- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-fluorophenyl-(methoxy- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-fluorophenyl-(ethoxy- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-fluorophenyl-(benzoxo- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-chlorophenyl-(methoxy- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-chlorophenyl-(ethoxy- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-chlorophenyl-(benzoxo- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-trifluorophenyl-(methoxy- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-trifluorophenyl-(ethoxy- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-trifluorophenyl-(benzoxo- $\alpha,\alpha$ -cycloleucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-nitrophenyl-(benzoxo-L-leucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[para-chlorophenyl-(benzoxo-L-leucinyl)]-phosphate;

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-[phenyl-(2-butyl-L-alaninyl)]-phosphate

Gemcitabine-[phenyl-(benzoxo-L-alaninyl)]-phosphate;

Gemcitabine-[para-chlorophenyl-(benzoxo-L-alaninyl)]-phosphate and

Gemcitabine-[para-chlorophenyl-(benzoxo- $\alpha,\alpha$ -dimethylglycinyl)]-phosphate.

21. (Previously presented) A compound according to claim 1 for use in the treatment

of cancer.


22. (Currently amended) ~~A method of Use of a compound according to claim 1 comprising the step of manufacturing of a medicament for the treatment of cancer comprising the compound of claim 1.~~

23. (Previously presented) A method for the treatment of cancer comprising administration to a patient in need of such treatment an effective dose of a compound according to claim 1.


24. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 with a pharmaceutically acceptable carrier, diluent or excipient.

25. (Previously presented) A method of preparing a pharmaceutical composition comprising the step of combining a compound according to claim 1 with a pharmaceutically acceptable excipient, carrier or diluent.

26. (Currently amended) A process for the preparation of a compound of formula I according to claim 1, the process comprising reacting of a compound of formula (III):



with a compound of formula (IV)



wherein Ar, n, Q, R, R', R'', X, Y, Z and Z' and Z''-have the meanings described in claim 1 and a double bond exists between position 3 and position 4.

27. (Canceled).
28. (Canceled).
29. (Canceled).
30. (Canceled).
31. (Canceled).
32. (Canceled).
33. (Canceled).
34. (Canceled).
35. (Canceled).
36. (Canceled).
37. (Canceled).
38. (Canceled).
39. (Canceled).
40. (Canceled).